|
1
|
Aging, progenitor cell exhaustion, and atherosclerosis.
|
Circulation
|
2003
|
5.19
|
|
2
|
The VIVA trial: Vascular endothelial growth factor in Ischemia for Vascular Angiogenesis.
|
Circulation
|
2003
|
3.45
|
|
3
|
Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): a randomised trial.
|
Lancet
|
2002
|
3.31
|
|
4
|
Results of a double-blind, placebo-controlled study to assess the safety of intramuscular injection of hepatocyte growth factor plasmid to improve limb perfusion in patients with critical limb ischemia.
|
Circulation
|
2008
|
2.82
|
|
5
|
A quantitative trait locus (LSq-1) on mouse chromosome 7 is linked to the absence of tissue loss after surgical hindlimb ischemia.
|
Circulation
|
2008
|
2.77
|
|
6
|
Pharmacological treatment of coronary artery disease with recombinant fibroblast growth factor-2: double-blind, randomized, controlled clinical trial.
|
Circulation
|
2002
|
2.39
|
|
7
|
A novel protective effect of erythropoietin in the infarcted heart.
|
J Clin Invest
|
2003
|
2.32
|
|
8
|
Regional angiogenesis with vascular endothelial growth factor in peripheral arterial disease: a phase II randomized, double-blind, controlled study of adenoviral delivery of vascular endothelial growth factor 121 in patients with disabling intermittent claudication.
|
Circulation
|
2003
|
1.90
|
|
9
|
The VEGF receptor Flt-1 spatially modulates Flk-1 signaling and blood vessel branching.
|
J Cell Biol
|
2008
|
1.82
|
|
10
|
Impaired angiogenesis after hindlimb ischemia in type 2 diabetes mellitus: differential regulation of vascular endothelial growth factor receptor 1 and soluble vascular endothelial growth factor receptor 1.
|
Circ Res
|
2007
|
1.80
|
|
11
|
Voluntary running induces fiber type-specific angiogenesis in mouse skeletal muscle.
|
Am J Physiol Cell Physiol
|
2004
|
1.71
|
|
12
|
Atherosclerotic Vascular Disease Conference: Writing Group III: pathophysiology.
|
Circulation
|
2004
|
1.65
|
|
13
|
A target-mediated model to describe the pharmacokinetics and hemodynamic effects of recombinant human vascular endothelial growth factor in humans.
|
Clin Pharmacol Ther
|
2002
|
1.63
|
|
14
|
A systems biology perspective on sVEGFR1: its biological function, pathogenic role and therapeutic use.
|
J Cell Mol Med
|
2009
|
1.59
|
|
15
|
Percutaneous intervention in peripheral artery disease improves calf muscle phosphocreatine recovery kinetics: a pilot study.
|
Vasc Med
|
2012
|
1.48
|
|
16
|
Preclinical models of human peripheral arterial occlusive disease: implications for investigation of therapeutic agents.
|
J Appl Physiol (1985)
|
2004
|
1.43
|
|
17
|
Increased phosphodiesterase type 5 levels in a mouse model of type 2 diabetes mellitus.
|
J Sex Med
|
2012
|
1.43
|
|
18
|
In mice with type 2 diabetes, a vascular endothelial growth factor (VEGF)-activating transcription factor modulates VEGF signaling and induces therapeutic angiogenesis after hindlimb ischemia.
|
Diabetes
|
2007
|
1.42
|
|
19
|
Oxidative phenotype protects myofibers from pathological insults induced by chronic heart failure in mice.
|
Am J Pathol
|
2007
|
1.29
|
|
20
|
Translational physiology: porcine models of human coronary artery disease: implications for preclinical trials of therapeutic angiogenesis.
|
J Appl Physiol (1985)
|
2003
|
1.25
|
|
21
|
Effect of hypoxia-inducible factor-1alpha gene therapy on walking performance in patients with intermittent claudication.
|
Circulation
|
2011
|
1.25
|
|
22
|
Plasma levels of soluble Tie2 and vascular endothelial growth factor distinguish critical limb ischemia from intermittent claudication in patients with peripheral arterial disease.
|
J Am Coll Cardiol
|
2008
|
1.22
|
|
23
|
Plasma nitrite response and arterial reactivity differentiate vascular health and performance.
|
Nitric Oxide
|
2009
|
1.20
|
|
24
|
Increased levels of apoptosis in gastrocnemius skeletal muscle in patients with peripheral arterial disease.
|
Vasc Med
|
2007
|
1.13
|
|
25
|
Therapeutic angiogenesis in chronically ischemic porcine myocardium: comparative effects of bFGF and VEGF.
|
Ann Thorac Surg
|
2004
|
1.12
|
|
26
|
Safety and efficacy of patient specific intramuscular injection of HGF plasmid gene therapy on limb perfusion and wound healing in patients with ischemic lower extremity ulceration: results of the HGF-0205 trial.
|
J Vasc Surg
|
2010
|
1.10
|
|
27
|
Angiogenesis in skeletal muscle precede improvements in peak oxygen uptake in peripheral artery disease patients.
|
Arterioscler Thromb Vasc Biol
|
2011
|
1.10
|
|
28
|
Skeletal muscle-specific genetic determinants contribute to the differential strain-dependent effects of hindlimb ischemia in mice.
|
Am J Pathol
|
2012
|
1.09
|
|
29
|
Adenovirus-mediated intraarterial delivery of PTEN inhibits neointimal hyperplasia.
|
Arterioscler Thromb Vasc Biol
|
2004
|
1.07
|
|
30
|
Deconditioning fails to explain peripheral skeletal muscle alterations in men with chronic heart failure.
|
J Am Coll Cardiol
|
2002
|
1.07
|
|
31
|
Systems biology of pro-angiogenic therapies targeting the VEGF system.
|
Wiley Interdiscip Rev Syst Biol Med
|
2010
|
1.06
|
|
32
|
Relationship between leg muscle capillary density and peak hyperemic blood flow with endurance capacity in peripheral artery disease.
|
J Appl Physiol (1985)
|
2011
|
1.03
|
|
33
|
MicroRNA-93 controls perfusion recovery after hindlimb ischemia by modulating expression of multiple genes in the cell cycle pathway.
|
Circulation
|
2013
|
1.01
|
|
34
|
Endothelial progenitor cells (EPCs) mobilized and activated by neurotrophic factors may contribute to pathologic neovascularization in diabetic retinopathy.
|
Am J Pathol
|
2009
|
1.01
|
|
35
|
A randomized, controlled study of autologous therapy with bone marrow-derived aldehyde dehydrogenase bright cells in patients with critical limb ischemia.
|
Catheter Cardiovasc Interv
|
2011
|
1.00
|
|
36
|
Relationship of physical function to vastus lateralis capillary density and metabolic enzyme activity in elderly men and women.
|
Aging Clin Exp Res
|
2008
|
0.95
|
|
37
|
Growth factors for therapeutic angiogenesis in peripheral arterial disease.
|
Curr Opin Cardiol
|
2007
|
0.95
|
|
38
|
State-of-the-Art Methods for Evaluation of Angiogenesis and Tissue Vascularization: A Scientific Statement From the American Heart Association.
|
Circ Res
|
2015
|
0.94
|
|
39
|
An engineered vascular endothelial growth factor-activating transcription factor induces therapeutic angiogenesis in ApoE knockout mice with hindlimb ischemia.
|
J Vasc Surg
|
2006
|
0.94
|
|
40
|
Engineered zinc finger-activating vascular endothelial growth factor transcription factor plasmid DNA induces therapeutic angiogenesis in rabbits with hindlimb ischemia.
|
Circulation
|
2004
|
0.94
|
|
41
|
Alteration in angiogenic and anti-angiogenic forms of vascular endothelial growth factor-A in skeletal muscle of patients with intermittent claudication following exercise training.
|
Vasc Med
|
2012
|
0.94
|
|
42
|
VEGF and soluble VEGF receptor-1 (sFlt-1) distributions in peripheral arterial disease: an in silico model.
|
Am J Physiol Heart Circ Physiol
|
2010
|
0.93
|
|
43
|
Testing clinical therapeutic angiogenesis using basic fibroblast growth factor (FGF-2).
|
Br J Pharmacol
|
2003
|
0.92
|
|
44
|
Computational kinetic model of VEGF trapping by soluble VEGF receptor-1: effects of transendothelial and lymphatic macromolecular transport.
|
Physiol Genomics
|
2009
|
0.90
|
|
45
|
Endothelial cell-by-cell profiling reveals the temporal dynamics of VEGFR1 and VEGFR2 membrane localization after murine hindlimb ischemia.
|
Am J Physiol Heart Circ Physiol
|
2013
|
0.90
|
|
46
|
The VEGF165b "ICE-o-form" puts a chill on the VEGF story.
|
Circ Res
|
2011
|
0.90
|
|
47
|
Mouse model of erectile dysfunction due to diet-induced diabetes mellitus.
|
Urology
|
2007
|
0.89
|
|
48
|
Plasma nitrite flux predicts exercise performance in peripheral arterial disease after 3months of exercise training.
|
Free Radic Biol Med
|
2010
|
0.89
|
|
49
|
Plasticity of myocytes and capillaries: a possible coordinating role for VEGF.
|
Circ Res
|
2004
|
0.88
|
|
50
|
Gene therapy from the perspective of systems biology.
|
Curr Opin Mol Ther
|
2010
|
0.87
|
|
51
|
A mouse model of hypercholesterolemia-induced erectile dysfunction.
|
J Sex Med
|
2007
|
0.87
|
|
52
|
Regional Angiogenesis with Vascular Endothelial Growth Factor (VEGF) in peripheral arterial disease: Design of the RAVE trial.
|
Am Heart J
|
2003
|
0.86
|
|
53
|
A sex-specific relationship between capillary density and anaerobic threshold.
|
J Appl Physiol (1985)
|
2009
|
0.85
|
|
54
|
Cholesterol feeding reduces vascular endothelial growth factor signaling in rabbit corporal tissues.
|
J Sex Med
|
2005
|
0.85
|
|
55
|
Therapeutic angiogenesis for critical limb ischemia: design of the hepatocyte growth factor therapeutic angiogenesis clinical trial.
|
Vasc Med
|
2004
|
0.85
|
|
56
|
Intracavernosal basic fibroblast growth factor improves vasoreactivity in the hypercholesterolemic rabbit.
|
J Sex Med
|
2006
|
0.85
|
|
57
|
Accelerated dual-contrast first-pass perfusion MRI of the mouse heart: development and application to diet-induced obese mice.
|
Magn Reson Med
|
2014
|
0.85
|
|
58
|
Adeno-associated virus serotype 9 administered systemically after reperfusion preferentially targets cardiomyocytes in the infarct border zone with pharmacodynamics suitable for the attenuation of left ventricular remodeling.
|
J Gene Med
|
2012
|
0.85
|
|
59
|
Angiogenic therapy for coronary artery and peripheral arterial disease.
|
Expert Rev Cardiovasc Ther
|
2005
|
0.84
|
|
60
|
Adeno-associated virus serotype 9-mediated overexpression of extracellular superoxide dismutase improves recovery from surgical hind-limb ischemia in BALB/c mice.
|
J Vasc Surg
|
2011
|
0.84
|
|
61
|
Differential effects of exercise training in men and women with chronic heart failure.
|
Am Heart J
|
2003
|
0.84
|
|
62
|
Myocyte specific overexpression of myoglobin impairs angiogenesis after hind-limb ischemia.
|
Arterioscler Thromb Vasc Biol
|
2008
|
0.84
|
|
63
|
Sodium nitrite in patients with peripheral artery disease and diabetes mellitus: safety, walking distance and endothelial function.
|
Vasc Med
|
2013
|
0.83
|
|
64
|
Design of the Del-1 for therapeutic angiogenesis trial (DELTA-1), a phase II multicenter, double-blind, placebo-controlled trial of VLTS-589 in subjects with intermittent claudication secondary to peripheral arterial disease.
|
Hum Gene Ther
|
2004
|
0.83
|
|
65
|
Engineered transcription factors for therapeutic angiogenesis.
|
Curr Opin Mol Ther
|
2007
|
0.83
|
|
66
|
Task force 3: Disclosure of relationships with commercial interests: policy for educational activities and publications.
|
J Am Coll Cardiol
|
2004
|
0.83
|
|
67
|
Myoglobin overexpression inhibits reperfusion in the ischemic mouse hindlimb through impaired angiogenesis but not arteriogenesis.
|
Am J Pathol
|
2013
|
0.82
|
|
68
|
Glycaemic control improves perfusion recovery and VEGFR2 protein expression in diabetic mice following experimental PAD.
|
Cardiovasc Res
|
2014
|
0.81
|
|
69
|
Angiogenesis therapy for the treatment of erectile dysfunction.
|
J Sex Med
|
2010
|
0.81
|
|
70
|
Vascular rarefaction in peripheral skeletal muscle after experimental heart failure.
|
Am J Physiol Heart Circ Physiol
|
2003
|
0.81
|
|
71
|
Systemic basic fibroblast growth factor induces favorable histological changes in the corpus cavernosum of hypercholesterolemic rabbits.
|
J Urol
|
2003
|
0.80
|
|
72
|
Impact of hormone replacement therapy on exercise training-induced improvements in insulin action in sedentary overweight adults.
|
Metabolism
|
2008
|
0.79
|
|
73
|
Regional cardiac sympathetic innervation early and late after transmyocardial laser revascularization.
|
J Card Surg
|
2004
|
0.79
|
|
74
|
Intramyocardial and intracoronary basic fibroblast growth factor in porcine hibernating myocardium: a comparative study.
|
J Thorac Cardiovasc Surg
|
2004
|
0.79
|
|
75
|
A comparison of mechanical and laser transmyocardial revascularization for induction of angiogenesis and arteriogenesis in chronically ischemic myocardium.
|
J Am Coll Cardiol
|
2002
|
0.79
|
|
76
|
Decreases in corporeal vascular endothelial growth factor expression precede vasoreactivity changes in cholesterol fed rabbits.
|
J Urol
|
2005
|
0.78
|
|
77
|
Is a simple biomarker for peripheral arterial disease on the horizon?
|
Circulation
|
2007
|
0.78
|
|
78
|
A VEGF trap inhibits the beneficial effect of bFGF on vasoreactivity in corporal tissues of hypercholesterolemic rabbits.
|
J Sex Med
|
2008
|
0.77
|
|
79
|
Alterations in microRNA expression in a murine model of diet-induced vasculogenic erectile dysfunction.
|
J Sex Med
|
2014
|
0.77
|
|
80
|
Growth factors for therapeutic angiogenesis in hypercholesterolemic erectile dysfunction.
|
Asian J Androl
|
2008
|
0.76
|
|
81
|
Alterations in endothelial cell proliferation and apoptosis contribute to vascular remodeling following hind-limb ischemia in rabbits.
|
Vasc Med
|
2002
|
0.75
|
|
82
|
High cholesterol feeding in C57/Blc6 mice alters expression within the VEGF receptor-ligand family in corporal tissue.
|
J Sex Med
|
2008
|
0.75
|
|
83
|
Basic fibroblast growth factor is upregulated in hibernating myocardium.
|
J Surg Res
|
2002
|
0.75
|
|
84
|
Effect of single dose of intravenous heparin on plasma levels of angiogenic growth factors.
|
Am J Cardiol
|
2003
|
0.75
|
|
85
|
Neovascularization in intimal hyperplasia is associated with vein graft failure after coronary artery bypass surgery.
|
Vasc Med
|
2003
|
0.75
|